Cargando…

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors

The purpose of this study was to investigate whether the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) can be used as supplementary tools to differentiate between benign, borderline, and malignant ovarian tumors. The ratio of patients with benign to borderline to malignant tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Tae Hui, Jeong, Yoon Young, Lee, Sun Jae, Choi, Youn Seok, Ryu, Jung Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911107/
https://www.ncbi.nlm.nih.gov/pubmed/35268446
http://dx.doi.org/10.3390/jcm11051355
_version_ 1784666699571658752
author Yun, Tae Hui
Jeong, Yoon Young
Lee, Sun Jae
Choi, Youn Seok
Ryu, Jung Min
author_facet Yun, Tae Hui
Jeong, Yoon Young
Lee, Sun Jae
Choi, Youn Seok
Ryu, Jung Min
author_sort Yun, Tae Hui
collection PubMed
description The purpose of this study was to investigate whether the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) can be used as supplementary tools to differentiate between benign, borderline, and malignant ovarian tumors. The ratio of patients with benign to borderline to malignant tumors was planned as 3:1:2 considering the incidence of each disease. Consecutive patients were enrolled retrospectively. Preoperative complete blood counts with differentials were investigated, and calculated NLRs and PLRs were analyzed. A total of 630 patients with ovarian tumors were enrolled in this study. The final histopathological results revealed that 318 patients had benign, 108 patients had epithelial borderline, and 204 patients had epithelial malignant ovarian tumors. The NLR and PLR were significantly higher in malignant than in benign or borderline ovarian tumors, and they did not differ significantly between benign and borderline ovarian tumors. The diagnostic cut-off value of NLR for differentiating between benign or borderline and malignant tumors was 2.36, whereas that of PLR for differentiating between benign/borderline and malignancy was 150.02. High preoperative NLR and PLR indicate that the likelihood of epithelial ovarian cancer is higher than that of benign or borderline tumors.
format Online
Article
Text
id pubmed-8911107
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89111072022-03-11 Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors Yun, Tae Hui Jeong, Yoon Young Lee, Sun Jae Choi, Youn Seok Ryu, Jung Min J Clin Med Article The purpose of this study was to investigate whether the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) can be used as supplementary tools to differentiate between benign, borderline, and malignant ovarian tumors. The ratio of patients with benign to borderline to malignant tumors was planned as 3:1:2 considering the incidence of each disease. Consecutive patients were enrolled retrospectively. Preoperative complete blood counts with differentials were investigated, and calculated NLRs and PLRs were analyzed. A total of 630 patients with ovarian tumors were enrolled in this study. The final histopathological results revealed that 318 patients had benign, 108 patients had epithelial borderline, and 204 patients had epithelial malignant ovarian tumors. The NLR and PLR were significantly higher in malignant than in benign or borderline ovarian tumors, and they did not differ significantly between benign and borderline ovarian tumors. The diagnostic cut-off value of NLR for differentiating between benign or borderline and malignant tumors was 2.36, whereas that of PLR for differentiating between benign/borderline and malignancy was 150.02. High preoperative NLR and PLR indicate that the likelihood of epithelial ovarian cancer is higher than that of benign or borderline tumors. MDPI 2022-03-01 /pmc/articles/PMC8911107/ /pubmed/35268446 http://dx.doi.org/10.3390/jcm11051355 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yun, Tae Hui
Jeong, Yoon Young
Lee, Sun Jae
Choi, Youn Seok
Ryu, Jung Min
Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors
title Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors
title_full Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors
title_fullStr Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors
title_full_unstemmed Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors
title_short Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors
title_sort neutrophil–lymphocyte and platelet–lymphocyte ratios in preoperative differential diagnosis of benign, borderline, and malignant ovarian tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911107/
https://www.ncbi.nlm.nih.gov/pubmed/35268446
http://dx.doi.org/10.3390/jcm11051355
work_keys_str_mv AT yuntaehui neutrophillymphocyteandplateletlymphocyteratiosinpreoperativedifferentialdiagnosisofbenignborderlineandmalignantovariantumors
AT jeongyoonyoung neutrophillymphocyteandplateletlymphocyteratiosinpreoperativedifferentialdiagnosisofbenignborderlineandmalignantovariantumors
AT leesunjae neutrophillymphocyteandplateletlymphocyteratiosinpreoperativedifferentialdiagnosisofbenignborderlineandmalignantovariantumors
AT choiyounseok neutrophillymphocyteandplateletlymphocyteratiosinpreoperativedifferentialdiagnosisofbenignborderlineandmalignantovariantumors
AT ryujungmin neutrophillymphocyteandplateletlymphocyteratiosinpreoperativedifferentialdiagnosisofbenignborderlineandmalignantovariantumors